• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Warrant (NQ:NXLIW)

0.0138 UNCHANGED
Last Price Updated: 3:18 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nexalin Technology, Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
February 08, 2024
Company’s International Reach Expanding with Latest Regulatory Approval 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
January 23, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Unveils Next-Generation HALO™ Clarity
January 11, 2024
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
December 18, 2023
Results published in General Psychiatry, a leading peer-reviewed journal 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
October 25, 2023
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
October 16, 2023
Study reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
August 07, 2023
New migraine data builds on prior clinical studies in depression 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
August 03, 2023
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
July 26, 2023
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
July 10, 2023
New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region
June 01, 2023
Wider Come to fund and conduct a total of four clinical trials, spanning insomnia, depression and other indications 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
January 24, 2023
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology CEO Provides Letter to Shareholders
January 05, 2023
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
November 14, 2022
From Nexalin Technology, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap